WHAT IS CLAIMED IS:

1. A compound of formula (I):



(I)

or a pharmaceutically-acceptable salt thereof.

2. A compound of formula (I):



(I) .

3. A crystalline form of the compound of formula (I):



(I)

wherein the crystalline form is characterized by a powder X-ray diffraction pattern comprising diffraction peaks at 2θ values of 11.4±0.2, 16.2±0.2, 16.6±0.2, 17.7±0.2, and 21.9±0.2.

4. The crystalline form of claim 3, wherein the powder X-ray diffraction pattern further comprises diffraction peaks at 2θ values of 8.9±0.2, 9.5±0.2, and 10.2±0.2.

5. The crystalline form of claim 4, wherein the powder X-ray diffraction pattern further comprises two or more additional diffraction peaks at 2θ values selected from 14.4±0.2, 19.0±0.2, 19.2±0.2, 19.8±0.2, 20.1±0.2, 20.4±0.2, 20.6±0.2, 20.8±0.2, 21.3±0.2, 25.9±0.2, 30.1±0.2, 30.5±0.2, 30.9±0.2, 32.6±0.2, and 33.8±0.2.

6. The crystalline form of claim 3, wherein the crystalline form is characterized by a differential scanning calorimetry trace recorded at a heating rate of 10 ºC per minute which shows a maximum in endothermic heat flow with a peak at 238.1 ºC ± 2 ºC.

7. A pharmaceutical composition comprising a compound of any one of claims 1 or 2, and a pharmaceutically-acceptable carrier.

8. A pharmaceutical composition comprising a crystalline form of any one of claims 3 to 6, and a pharmaceutically-acceptable carrier.

9. The pharmaceutical composition of claim 7 further comprising one or more additional therapeutic agents.

10. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition is an ointment or a cream.

11. The pharmaceutical composition of claim 7, wherein compound (I), or a pharmaceutically acceptable salt thereof, is present at between 0.1 and 10 % by weight.

12. The pharmaceutical composition of claim 7, wherein compound (I), or a pharmaceutically acceptable salt thereof, is present at between 0.25 and 5% by weight.

13. The pharmaceutical composition of claim 7, wherein compound (I), or a pharmaceutically acceptable salt thereof, is present at between 0.05 and 0.5% by weight.

14. Use of a compound of claim 1 or 2, in the manufacture of a medicament for the treatment of an inflammatory or autoimmune skin disease in a mammal.

15. The use of claim 14 in the manufacture of a medicament for the treatment of an inflammatory skin disease in a mammal.

16. The use of claim 15, wherein the inflammatory skin disease is atopic dermatitis.

17. The use of claim 16, wherein the atopic dermatitis is moderate to severe atopic dermatitis.

18. The use of claim 16, wherein the atopic dermatitis is mild to moderate atopic dermatitis.

19. The use of claim 14 in the manufacture of a medicament for the treatment of an autoimmune skin disease in a mammal.

20. The use of claim 19, wherein the autoimmune skin disease is alopecia areata.

21. The use of claim 14, wherein the inflammatory or autoimmune skin disease is selected from the group consisting of: vitiligo, prurigo nodularis, lichen planus, contact dermatitis, skin manifestations of graft versus host disease, pemphigoid, discoid lupus, lichen sclerosus, lichen planopilaris, psoriasis, and foliculitis decalvans.

22. A process for preparing a compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, comprising:

(a) reacting a compound of formula (II):



(II)

wherein R is a $C_{1-12}$ alkyl group, with a reducing agent and

(b) optionally forming a pharmaceutically acceptable salt

to provide a compound of formula (I), or a pharmaceutically acceptable salt thereof.

23. The process of claim 22, wherein the reducing agent is selected from the group consisting of $LiAlH_4$, $NaBH_4$, and $LiBH_4$.

24. The process of claim 22, wherein R is ethyl.

25. The process of claim 22, wherein the compound of formula (II) is obtained by coupling a compound of formula (III)



(III)

wherein X is a halogen, with a compound of formula 1-9



1-9 .

26. A compound of formula (II):



(II)

or a pharmaceutically acceptable salt thereof,

wherein R is a $C_{1-12}$ alkyl group.

27. The compound of Claim 26, wherein R is ethyl.

28. A compound of formula (III):




(III)

or a pharmaceutically acceptable salt thereof,

wherein R is a $C_{1-12}$ alkyl group and X is halogen.

29. The compound of claim 28, wherein R is ethyl and X is chloro.